Evelien M. J. Beelen

Evelien M. J. Beelen

Auto-generated profile, based on publicly available information

Evelien M. J. Beelen

Department of Gastroenterology and Hepatology, Erasmus University Medical Center , Rotterdam , The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
EBEvelien M.J. Beelen
Evelien M.J. Beelen
DNDaan Nieboer
Daan Nieboer
JAJeanine H.C. Arkenbosch
Jeanine H.C. Arkenbosch
MRMiguel D. Regueiro
Miguel D. Regueiro
JSJack Satsangi
Jack Satsangi
AVAnnemarie C. de Vries
Annemarie C. de Vries
The superiority of anti-TNF-α agents to thiopurines for the prevention of postoperative recurrence of Crohn's disease (CD) after ileocolonic resection remains controversial. In this meta-analysis of individual participant data (IPD), the effect of both strategies was compared and assessed after risk stratification. After a systematic literature search, IPD were requested from randomized controlled trials investigating thiopurines and/or anti-TNF-α agents after ileocolonic resection. Primary outcome was endoscopic recurrence (ER) (Rutgeerts score ≥i2) and secondary outcomes were clinical recurrence (Harvey-Bradshaw Index/Crohn's Disease Activity Index score) and severe ER (Rutgeerts score ≥i3). A fixed effect network meta-analysis was performed. Subgroup effects were assessed and a prediction model was established using Poisson regression models, including sex, smoking, Montreal classification, CD duration, history of prior resection and previous exposure to anti-TNF-α or thiopurines. In the meta-analysis of IPD, 645 participants from 6 studies were included. In the total population, a superior effect was demonstrated for anti-TNF-α compared with thiopurine prophylaxis for ER (relative risk [RR], 0.52; 95% confidence interval [CI], 0.33-0.80), clinical recurrence (RR, 0.50; 95% CI, 0.26-0.96), and severe ER (RR, 0.41; 95% CI, 0.21-0.79). No differential subgroup effects were found for ER. In Poisson regression analysis, previous exposure to anti-TNF-α and penetrating disease behavior were associated with ER risk. The advantage of anti-TNF-α agents as compared with thiopurines was observed in low- and high-risk groups. Anti-TNF-α is superior to thiopurine prophylaxis for the prevention of endoscopic and clinical postoperative CD recurrence after ileocolonic resection. The advantage of anti-TNF-α agents was confirmed in subgroup analysis and after risk stratification.

12 September 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
JAJeanine H C Arkenbosch
Jeanine H C Arkenbosch
EBEvelien M J Beelen
Evelien M J Beelen
GDGerard Dijkstra
Gerard Dijkstra
MRMariëlle Romberg-Camps
Mariëlle Romberg-Camps
MDMarjolijn Duijvestein
Marjolijn Duijvestein
AVAnnemarie C de Vries
Annemarie C de Vries
To prevent recurrence after ileocolonic resection [ICR] in Crohn’s disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts’ score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61–0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64–0.81]. Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.

8 April 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
CSCorinne E.G.M. Spooren
Corinne E.G.M. Spooren
TLToine M. Lodewick
Toine M. Lodewick
EBEvelien M.J. Beelen
Evelien M.J. Beelen
DDDavid P.J. van Dijk
David P.J. van Dijk
MBMartijn J.L. Bours
Martijn J.L. Bours
DJDaisy M.A.E. Jonkers
Daisy M.A.E. Jonkers
Background and Aim: Myosteatosis is a prognostic factor in cancer and liver cirrhosis. It can be determined noninvasively using computed tomography or, as shown recently, by magnetic resonance (MR) imaging. The primary aim was to analyze the reproducibility of skeletal muscle signal intensity on routine MR‐enterographies, as indicator of myosteatosis, in Crohn's disease (CD) and to explore the association between skeletal muscle signal intensity at diagnosis with time to intestinal resection.Methods: CD patients undergoing MR‐enterography within 6 months from diagnosis and having a maximum of 5 years follow‐up were included. Skeletal muscle signal intensity was analyzed on T1‐weighted fat‐saturated post‐contrast images. Intra‐observer and inter‐observer reproducibilities were assessed by intra‐class correlation coefficient and Cohen's kappa. Intra‐observer and inter‐observer variabilities were determined by Pearson correlation coefficient and displayed by Bland–Altman plots. Time to intestinal resection was studied by Kaplan–Meier analysis.Results: Median time between diagnosis and MR‐enterography was 5 weeks (inter‐quartile range 1–9) in 35 CD patients. Skeletal muscle signal intensity showed good intra‐class correlation and substantial agreement (for intra‐observer, intraclass correlation coefficient = 0.948, κ = 0.677; and inter‐observer reproducibility, intraclass correlation coefficient = 0.858, κ = 0.622). Resection free survival was shorter in the low skeletal muscle signal intensity group (P = 0.037).Conclusion: Skeletal muscle signal intensity on routine MR‐enterographies is reproducible and was associated with unfavorable disease outcome, indicating potential clinical relevance.

5 September 2023 in BJS Open
Verified
Journal Article
Open access
PDF file
EBEvelien M J Beelen
Evelien M J Beelen
JAJeanine H C Arkenbosch
Jeanine H C Arkenbosch
NENicole S Erler
Nicole S Erler
JSJasmijn A M Sleutjes
Jasmijn A M Sleutjes
FHFrank Hoentjen
Frank Hoentjen
AVAnnemarie C de Vries
Annemarie C de Vries
Background: The advantage of early ileocecal resection after Crohn’s disease diagnosis is a matter of debate. This study aims to assess the timing of ileocecal resection on prognosis, after correction for possible confounders. Methods: Patients with Crohn's disease with primary ileocecal resection between 2000 and 2019 were included in a retrospective multicentre cohort. The primary endpoint was endoscopic recurrence (Rutgeerts score ≥i2b) within 18 months. Secondary endpoints were escalation of inflammatory bowel disease medication within 18 months and re-resection during follow-up. The association between timing of ileocecal resection and these endpoints was investigated using multivariable proportional hazard models, corrected for covariates including Montreal classification, postoperative prophylaxis, smoking, indication for surgery, medication before ileocecal resection, perianal fistulas, surgical approach, histology, length of resected segment and calendar year. Results: In 822 patients ileocecal resection was performed after a median of 3.1 years (i.q.r. 0.7–8.0) after Crohn's disease diagnosis. The lowest incidence of endoscopic recurrence, escalation of inflammatory bowel disease medication and re-resection was observed for patients undergoing ileocecal resection shortly after diagnosis (0–1 months). After correction for covariates, patients with ileocecal resection at 0, 4 and 12 months after diagnosis had a cumulative incidence of 35 per cent, 48 per cent and 39 per cent for endoscopic recurrence, 20 per cent, 29 per cent and 28 per cent for escalation of inflammatory bowel disease medication and 20 per cent, 30 per cent and 34 per cent for re-resection, respectively. In the multivariable model ileocolonic disease (HR 1.39 (95 per cent c.i. 1.05 to 1.86)), microscopic inflammation of proximal and distal resection margins (HR 2.20 (95 per cent c.i. 1.21 to 3.87)) and postoperative prophylactic biological and immunomodulator (HR 0.16 (95 per cent c.i. 0.05 to 0.43)) were associated with endoscopic recurrence. Conclusion: The timing of ileocecal resection was not associated with a change of disease course; in the multivariable model, the postoperative recurrence was not affected by timing of ileocecal resection.

8 November 2018 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
PDF file
JGJorn C. Goet
Jorn C. Goet
EBEvelien M. J. Beelen
Evelien M. J. Beelen
KBKatharina E. Biermann
Katharina E. Biermann
AGAnnette H. Gijsbers
Annette H. Gijsbers
WSW. Rudolph Schouten
W. Rudolph Schouten
AVAnnemarie C. de Vries
Annemarie C. de Vries
The risk of gallstone disease necessitating cholecystectomy after ileal resection (IR) in Crohn’s disease (CD) patients is not well established. We studied the incidence, cumulative and relative risk of cholecystectomy after IR in CD patients, and associated risk factors.

10 August 2019 in Gut
Verified
Journal Article
Open access
PDF file
EBEvelien M J Beelen
Evelien M J Beelen
CWC Janneke van der Woude
C Janneke van der Woude
AVAnnemarie C de Vries
Annemarie C de Vries
With great interest we have read the manuscript written by Murthy et al, published in Gut in June 2019, on the influence of anti-tumour necrosis factor alpha (TNFα) therapy introduction on the rate of hospitalisation and intestinal resection rates in IBD. 1 Despite the difference in the source of data between both studies (Canada: health administrative data and the Netherlands: nationwide pathology database), a declining rate of intestinal resections in Crohn's disease has been confirmed in Canada, at equal rates as the decline that has been observed in the Netherlands. 2 The authors used an advanced statistical method to analyse the impact of anti-TNFα introduction on (among other end points) the rate of intestinal resection. However, in our opinion, the hypothesised direct relationship between introduction of anti-TNFα and a decline in intestinal resection rate is vastly oversimplified for two important reasons. First, several other factors that have influenced both (early) diagnosis and management of Crohn's disease should be taken into account. Important changes over the past decades include improved access to endoscopy, less complications at diagnosis and development of strict and non-invasive monitoring strategies. In their original hypothesis, the authors also state the expectation that